(Reuters) – Drug developer Ocugen Inc will co-develop India-based Bharat Biotech’s COVID-19 vaccine candidate for the U.S. market, the companies said on Tuesday.
The vaccine candidate, Covaxin, is currently in a late-stage study in India.
(Reporting by Trisha Roy in Bengaluru; Editing by Anil D’Silva)
